Canada markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
259.80-1.83 (-0.70%)
At close: 04:00PM EST
259.50 -0.30 (-0.12%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close261.63
Open262.99
Bid247.68 x 1100
Ask275.85 x 1300
Day's Range258.08 - 264.20
52 Week Range118.18 - 280.62
Volume231,874
Avg. Volume270,354
Market Cap27.411B
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia

    BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., January 19, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Business Wire

    BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, January 19, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one pri

  • Business Wire

    BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, January 18, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS® (carfilzomib), a proteosome inhibitor licensed-in from Amgen, is included for the first time and XGEVA® (denosumab), a